# A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

> **NCT04831658** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mingzhi Zhang** · enrollment: 40 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** the dose-escalation phase

## Key facts

- **NCT ID:** NCT04831658
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-29
- **Primary completion:** 2023-09-15
- **Final completion:** 2024-09-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04831658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04831658, "A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04831658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*